Literature DB >> 1321294

Human immunodeficiency virus type 1 gag-pol frameshifting is dependent on downstream mRNA secondary structure: demonstration by expression in vivo.

N T Parkin1, M Chamorro, H E Varmus.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) Gag-Pol fusion polyprotein is produced via ribosomal frameshifting. Previous studies in vitro and in Saccharomyces cerevisiae have argued against a significant role for RNA secondary structure 3' of the shift site, in contrast with other systems, in which such structure has been shown to be required. Here we show, by expressing the HIV-1 gag-pol domain in cultured vertebrate cells, that a stem-loop structure 3' of the HIV-1 shift site is indeed important for wild-type levels of frameshifting in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321294      PMCID: PMC241392     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  SV40-transformed simian cells support the replication of early SV40 mutants.

Authors:  Y Gluzman
Journal:  Cell       Date:  1981-01       Impact factor: 41.582

3.  Identification and characterization of human immunodeficiency virus type 1 gag-pol fusion protein in transfected mammalian cells.

Authors:  C Peng; N T Chang; T W Chang
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  Continuous tissue culture cell lines derived from chemically induced tumors of Japanese quail.

Authors:  C Moscovici; M G Moscovici; H Jimenez; M M Lai; M J Hayman; P K Vogt
Journal:  Cell       Date:  1977-05       Impact factor: 41.582

5.  Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production.

Authors:  J Park; C D Morrow
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  An RNA pseudoknot and an optimal heptameric shift site are required for highly efficient ribosomal frameshifting on a retroviral messenger RNA.

Authors:  M Chamorro; N Parkin; H E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

7.  Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA.

Authors:  M J Zoller; M Smith
Journal:  Nucleic Acids Res       Date:  1982-10-25       Impact factor: 16.971

8.  Translational frameshifting in the Escherichia coli dnaX gene in vitro.

Authors:  Z Tsuchihashi
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

9.  Mutational analysis of the RNA pseudoknot component of a coronavirus ribosomal frameshifting signal.

Authors:  I Brierley; N J Rolley; A J Jenner; S C Inglis
Journal:  J Mol Biol       Date:  1991-08-20       Impact factor: 5.469

10.  Expression and frameshifting but extremely inefficient proteolytic processing of the HIV-1 gag and pol gene products in stably transfected rodent cell lines.

Authors:  D Moosmayer; H Reil; M Ausmeier; J G Scharf; H Hauser; K D Jentsch; G Hunsmann
Journal:  Virology       Date:  1991-07       Impact factor: 3.616

View more
  88 in total

1.  Programmed ribosomal frameshifting: much ado about knotting!

Authors:  S L Alam; J F Atkins; R F Gesteland
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

2.  Specific mutations in a viral RNA pseudoknot drastically change ribosomal frameshifting efficiency.

Authors:  Y G Kim; L Su; S Maas; A O'Neill; A Rich
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

3.  The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structure.

Authors:  Jonathan D Dinman; Sara Richter; Ewan P Plant; Ronald C Taylor; Amy B Hammell; Tariq M Rana
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

4.  Structural analysis of the -1 ribosomal frameshift elements in giardiavirus mRNA.

Authors:  L Li; A L Wang; C C Wang
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  Genetic diversity: frameshift mechanisms alter coding of a gene (Epstein-Barr virus LF3 gene) that contains multiple 102-base-pair direct sequence repeats.

Authors:  Shao-An Xue; M D Jones; Qi-Long Lu; J M Middeldorp; Beverly E Griffin
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

6.  Solution structure of the HIV-1 frameshift inducing stem-loop RNA.

Authors:  David W Staple; Samuel E Butcher
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

7.  A -1 ribosomal frameshift element that requires base pairing across four kilobases suggests a mechanism of regulating ribosome and replicase traffic on a viral RNA.

Authors:  Jennifer K Barry; W Allen Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-30       Impact factor: 11.205

8.  Strategies for recognition of stem-loop RNA structures by synthetic ligands: application to the HIV-1 frameshift stimulatory sequence.

Authors:  Prakash B Palde; Leslie O Ofori; Peter C Gareiss; Jaclyn Lerea; Benjamin L Miller
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

9.  Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.

Authors:  Lucile Larrouy; C Chazallon; R Landman; C Capitant; G Peytavin; G Collin; C Charpentier; A Storto; G Pialoux; C Katlama; P M Girard; P Yeni; J P Aboulker; F Brun-Vezinet; D Descamps
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

10.  Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.

Authors:  Kirsten M Stray; Christian Callebaut; Bärbel Glass; Luong Tsai; Lianhong Xu; Barbara Müller; Hans-Georg Kräusslich; Tomas Cihlar
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.